-continued

```
Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
    210                 215                 220

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
225                 230                 235                 240

Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala
                245                 250                 255

Asn Pro Asn Lys Asn Asn Gln Gly Asn Gly Gln Gly His Asn Met Pro
            260                 265                 270

Asn Asp Pro Asn Arg Asn Val Asp Glu Asn Ala Asn Ala Asn Ser Ala
        275                 280                 285

Val Lys Asn Asn Asn Asn Glu Glu Pro Ser Asp Lys His Ile Lys Glu
    290                 295                 300

Tyr Leu Asn Lys Ile Gln Asn Ser Leu Ser Thr Glu Trp Ser Pro Cys
305                 310                 315                 320

Ser Val Thr Cys Gly Asn Gly Ile Gln Val Arg Ile Lys Pro Gly Ser
                325                 330                 335

Ala Asn Lys Pro Lys Asp Glu Leu Asp Tyr Ala Asn Asp Ile Glu Lys
            340                 345                 350

Lys Ile Cys Lys Met Glu Lys Cys Ser Ser Val Phe Asn Val Val Asn
        355                 360                 365

Ser
```

1. A recombinant *Plasmodium falciparum* circumsporozoite protein (rCSP), said rCSP characterized by:

an N-terminal region that lacks twenty to twenty-five N-terminus amino acid residues of native *P. falciparum* circumsporozoite protein;

a reduced number of NANP repeats compared to native *P. falciparum* circumsporozoite protein; and

at least 85% homology to SEQ ID NO:2.

2. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP lacks Met_1 to Cys_{25} of the N-terminal region of native *P. falciparum* circumsporozoite protein.

3. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP has 18 or 19 NANP repeats.

4. The recombinant *P. falciparum* CSP of claim **3**, wherein the rCSP has 19 NANP repeats.

5. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP has a 0 to 3 NVDP repeats.

6. The recombinant *P. falciparum* CSP of claim **5**, wherein the rCSP has 3 NVDP repeats.

7. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP has a C-terminal region that lacks ten to fourteen C-terminus amino acid residues of native *P. falciparum* circumsporozoite protein.

8. The recombinant *P. falciparum* CSP of claim **7**, wherein the rCSP ends at Ser_{383}.

9. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP has at least 90% homology to SEQ ID NO:2.

10. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP has at least 95% homology to SEQ ID NO:2.

11. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP comprises SEQ ID NO:2.

12. The recombinant *P. falciparum* CSP of claim **1**, wherein the rCSP comprises SEQ ID NO:8.

13. A nucleotide sequence encoding the recombinant *P. falciparum* CSP of claim **1**.

14. A nucleotide sequence comprising SEQ ID NO:1 or a sequence that is at least 85% homologous to SEQ ID NO:1.

15. The nucleotide sequence of claim **14**, wherein the nucleotide sequence is 90% homologous to SEQ ID NO:1.

16. The nucleotide sequence of claim **14**, wherein the nucleotide sequence is 95% homologous to SEQ ID NO:1.

17. The nucleotide sequence of claim **13**, wherein the nucleotide sequence comprises at least one expression tag.

18. The nucleotide sequence of claim **17**, wherein the nucleotide sequence is SEQ ID NO:5.

19. An expression vector for *E. coli* comprising the nucleotide sequence of claim **13**.

20. A bacterial cell transformed with the expression vector of claim **19**.

21. The bacterial cell of claim **20**, wherein the cell is an *E. coli* cell.

22. The bacterial cell of claim **21**, wherein the *E. coli* is SHUFFLE™ strain.

23. The bacterial cell of claim **21**, wherein the *E. coli* cell expresses a recombinant *P. falciparum* CSP as a soluble protein.

24. An anti-malaria vaccine comprising:

a recombinant *Plasmodium falciparum* CSP according to claim **1**; and

one or more adjuvants.

25. The vaccine of claim **24**, wherein the adjuvant is Montanide ISA 720.

26. The vaccine of claim **24**, wherein the vaccine has an endotoxin level less than about 5 endotoxin units per microgram of protein.

27. The vaccine of claim **24**, wherein the vaccine comprises less than about 1 ng/ml of bacterial host proteins.